Evidence map›Paper›PMID 38613690›Full record

ArticleJournal of gastroenterology2024

Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals.

Chen-Hua Liu, Yu-Ping Chang, Yu-Jen Fang, Pin-Nan Cheng, Chi-Yi Chen, Wei-Yu Kao, Chih-Lin Lin, Sheng-Shun Yang, Yu-Lueng Shih, Cheng-Yuan Peng and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Chen-Hua Liu *Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Yu-Ping Chang *Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Yu-Jen FangDepartment of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Yunlin, Taiwan.
Pin-Nan ChengDepartment of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Chi-Yi ChenDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
Wei-Yu KaoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
Chih-Lin LinDepartment of Gastroenterology, Taipei City Hospital, Ren-Ai Branch, Taipei, Taiwan.
Sheng-Shun YangDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Yu-Lueng ShihDivision of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Cheng-Yuan PengCenter for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Ming-Chang TsaiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
Shang-Chin HuangDepartment of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan.
Tung-Hung SuDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Tai-Chung TsengDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Chun-Jen LiuDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Pei-Jer ChenDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Jia-Horng KaoDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. kaojh@ntu.edu.tw.ORCID 0000-0002-2442-7952

Funding

National Science and Technology Council NSTC 112-2314-B-002 131-MY3National Taiwan University Hospital 112-IF0004
6 · The paper itself

Abstract

backgroundInformation on the dynamics of metabolic dysfunction-associated steatotic liver disease (MASLD) among hepatitis C virus patients achieving sustained virologic response (SVR

methodsWe enrolled 1512 eligible participants in this prospective study. MASLD was defined by a controlled attenuation parameter (CAP) of ≥248 dB/m utilizing vibration-controlled transient elastography in conjunction with presence of  ≥1 cardiometabolic risk factor. The distribution of MASLD and the changes in CAP were evaluated before treatment and at SVR

resultsThe prevalence of MASLD decreased from 45.0% before treatment to 36.1% at SVR

conclusionsThe prevalence of MASLD decreased after achieving SVR

Indexed as

Antiviral AgentsFatty LiverHepatitis C, ChronicSustained Virologic ResponseAdultAgedDiabetes Mellitus, Type 2Elasticity Imaging TechniquesFemaleHumansMaleMiddle AgedPrevalenceProspective StudiesRisk FactorsAntiviral AgentsControlled attenuation parameterDirect-acting antiviralHepatitis C virusMetabolic dysfunction-associated steatotic liver diseaseSustained virologic response

Identifiers

PMID38613690

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.